Brookfield Renewable Energy Partners LP (NYSE:BEP) ended the last trading day at $26.86. Company weekly volatility is calculated as 1.98%. Brookfield Renewable Energy Partners LP (NYSE:BEP) showed a weekly performance of -0.67%.
Brookfield Renewable Energy Partners LP (NYSE:BEP) announced an agreement to acquire a hydroelectric portfolio in Pennsylvania from Talen Energy for $860 million. Brookfield Renewable will acquire and fund the transaction with institutional partners and maintain an economic interest in the portfolio of approximately 40 percent. A portion of the purchase price will be funded with third party investment grade, non-recourse financing expected to close concurrently with the transaction.
Turkcell Iletisim Hizmetleri AS (NYSE:TKC) ended the last trading day at $9.76. Company weekly volatility is calculated as 1.72% and price to cash ratio as 5.39. Turkcell Iletisim Hizmetleri AS (NYSE:TKC) showed a weekly performance of 1.67%.
Turkcell Iletisim Hizmetleri AS (NYSE:TKC) and the Turkish Football Federation have announced that Turkcell will be the communication sponsor of “Spor Toto Super Lig”, Turkey’s top football league, in 2015-2016. Turkcell will also be the main sponsor of the Turkish Cup in 2015-2016, which will take the name “Turkcell Super Cup”.
On 21 October, Amicus Therapeutics, Inc. (NASDAQ:FOLD) shares fell -7.36% and was closed at $6.17. FOLD EPS growth in last 5 year was -26.20%. Amicus Therapeutics, Inc. (NASDAQ:FOLD) year to date (YTD) performance is -25.84%.
Amicus Therapeutics, Inc. (NASDAQ: FOLD) and its chief executive officer, John F. Crowley, were named as defendants in a lawsuit alleging that they violated the Federal Securities Laws filed by Block & Leviton LLP. The lawsuit, filed in Federal Court in the District of New Jersey, Lifestyle Investments, LLC v. Amicus Therapeutics, Inc., alleges that defendants issued a press release on September 15, 2015 in which they misrepresented that Amicus received positive news from a Pre-New Drug Application (“NDA”) meeting with the Food and Drug Administration (“FDA”) for its NDA for its oral small molecule pharmacological chaperone migalastat for the treatment of Fabry disease. Defendants publicly stated that, based on information provided by the FDA the NDA was on track for filing in the fourth quarter of 2015.
Fortress Biotech, Inc. (NASDAQ:FBIO) shares fell -0.73% in last trading session and ended the day at $2.73. And its has a return on assets of -30.20%. Fortress Biotech, Inc. (NASDAQ:FBIO) quarterly performance is -24.17%.
Checkpoint Therapeutics, Inc. (“Checkpoint”), a Fortress Biotech, Inc. (NASDAQ:FBIO), announced that Mr. James F. Oliviero, III, has been appointed President and Chief Executive Officer (CEO). Mr. Oliviero will also be appointed to Checkpoint’s Board of Directors. Michael S. Weiss, will remain as Executive Chairman. Michael S. Weiss, Executive Chairman of Checkpoint stated, “We are very excited to have James join Checkpoint. James is a seasoned biotech executive with strong operational and financial expertise. James’ experience ranges from capital raising and managing relationships with Wall Street to playing an instrumental role in the approval of Auryxia(TM), a drug we licensed and developed together at Keryx.
CaesarStone Sdot-Yam Ltd. (NASDAQ:CSTE) caters to the Industrial Goods space. It has a net profit margin of 18.30% and weekly performance is 14.82%. On the last day of trading company shares ended up at $37.50. CaesarStone Sdot-Yam Ltd. (NASDAQ:CSTE) distance from 50-day simple moving average (SMA50) is -4.21%.
Caesarstone Sdot-Yam Ltd. (NASDAQ:CSTE), announced that it will release its earnings results for the third quarter ended September 30, 2015 on Wednesday, November 4, 2015 before the market opens. Yosef Shiran, the Company’s Chief Executive Officer, and Yair Averbuch, the Company’s Chief Financial Officer, will host a conference call on the same day at 8:30 a.m. ET to discuss the results, followed by a question and answer session for the investment community.
Leave a Reply